DE69435303D1 - Er behandlung von krankheiten bei denen eine cytok - Google Patents
Er behandlung von krankheiten bei denen eine cytokInfo
- Publication number
- DE69435303D1 DE69435303D1 DE69435303T DE69435303T DE69435303D1 DE 69435303 D1 DE69435303 D1 DE 69435303D1 DE 69435303 T DE69435303 T DE 69435303T DE 69435303 T DE69435303 T DE 69435303T DE 69435303 D1 DE69435303 D1 DE 69435303D1
- Authority
- DE
- Germany
- Prior art keywords
- cytok
- treating diseases
- compositions
- methods
- relates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 208000024908 graft versus host disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000013508 migration Methods 0.000 abstract 1
- 230000005012 migration Effects 0.000 abstract 1
- 230000035939 shock Effects 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0325—Animal model for autoimmune diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0368—Animal model for inflammation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6339993A | 1993-05-17 | 1993-05-17 | |
PCT/US1994/005433 WO1994026307A1 (en) | 1993-05-17 | 1994-05-16 | Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69435303D1 true DE69435303D1 (de) | 2010-09-02 |
Family
ID=22048950
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69435303T Expired - Lifetime DE69435303D1 (de) | 1993-05-17 | 1994-05-16 | Er behandlung von krankheiten bei denen eine cytok |
Country Status (7)
Country | Link |
---|---|
EP (2) | EP1741779A3 (de) |
JP (1) | JP4708510B2 (de) |
AT (1) | ATE474597T1 (de) |
AU (1) | AU692159B2 (de) |
CA (1) | CA2163211C (de) |
DE (1) | DE69435303D1 (de) |
WO (1) | WO1994026307A1 (de) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6863890B1 (en) * | 1993-02-26 | 2005-03-08 | Advanced Biotherapy, Inc. | Treatment of AIDS with antibodies to gamma interferon, alpha interferon and TNF-alpha |
JP3578787B2 (ja) * | 1993-05-14 | 2004-10-20 | ラホヤ インスティチュート フォア アレルギー アンド イムノロジー | 生物学的に活性なポリペプチドの組換え製造方法 |
US6774227B1 (en) * | 1993-05-17 | 2004-08-10 | Cytokine Pharmasciences, Inc. | Therapeutic uses of factors which inhibit or neutralize MIF activity |
SI9400363A (en) * | 1994-09-19 | 1996-08-31 | Mozetic Francky Bojana | Human macrophage migration inhibitory factor of nonlymphoid origin, expression of mif in e. coli and purification of recombinant protein |
WO1996015242A2 (en) * | 1994-11-16 | 1996-05-23 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Methods for inhibiting cell proliferation by inhibiting the mitogenic activity of macrophage migration inhibitory factor |
US5910427A (en) * | 1995-06-22 | 1999-06-08 | La Jolla Institute For Allergy And Immunology | Antigen non-specific glycosylation inhibiting factor derivatives |
US6420188B1 (en) * | 1996-02-16 | 2002-07-16 | The Picower Institute For Medical Research | Screening assay for the identification of inhibitors for macrophage migration inhibitory factor |
WO2000046404A1 (en) * | 1999-02-05 | 2000-08-10 | Wrair Walter Reed Army Institute Of Research | Method of diagnosing of exposure to toxic agents by measuring distinct pattern in the levels of expression of specific genes |
CA2455915C (en) * | 2001-03-29 | 2013-05-14 | Cytokine Pharmasciences, Inc. | Methods and compositions for using mhc class ii invariant chain polypeptide as a receptor for macrophage migration inhibitory factor |
UY27304A1 (es) | 2001-05-24 | 2002-12-31 | Avanir Pharmaceuticals | Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación |
WO2003090782A1 (fr) | 2002-04-26 | 2003-11-06 | Takeda Chemical Industries, Ltd. | Inhibiteur de la mort cellulaire |
US7105336B2 (en) * | 2002-10-07 | 2006-09-12 | Biogaia Ab | Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter |
TW200418829A (en) | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
JP2007503388A (ja) | 2003-08-22 | 2007-02-22 | アバニール・ファーマシューティカルズ | マクロファージ遊走阻止因子の阻害剤としての置換ナフチリジン誘導体、およびヒト疾患の治療におけるそれらの使用 |
WO2005058304A1 (en) * | 2003-12-17 | 2005-06-30 | Cortical Pty Ltd | Implantable device containing inhibitor of macrophage migration inhibitory factor |
EP1819731A4 (de) | 2004-12-08 | 2013-02-13 | Immunomedics Inc | Verfahren und zusammensetzung zur immuntherapie und für den nachweis von entzündungs- und dysregulatorischen immunerkrankungen, infektionserkrankungen, pathologischer angiogenese und krebs |
JP2008534502A (ja) | 2005-03-24 | 2008-08-28 | アバニール・ファーマシューティカルズ | マクロファージ遊走阻止因子の阻害剤としてのチエノピリジノン誘導体 |
DK1874821T3 (da) * | 2005-04-26 | 2013-07-08 | Trion Pharma Gmbh | Kombination af antistoffer med glykokortikoider til behandling af kræft |
CN102088993A (zh) * | 2008-03-20 | 2011-06-08 | 卡罗勒斯治疗公司 | 炎症的治疗方法 |
EP2731970B1 (de) | 2011-07-15 | 2018-11-28 | MorphoSys AG | Antikörper mit kreuzreaktion auf makrophagenmigrations-inhibitorfaktor (mif) und d-dopachrom-tautomerase (d-dt) |
EP2748613B1 (de) | 2011-10-07 | 2021-05-05 | Baxalta GmbH | Oxmif als diagnosemarker |
JP2014530361A (ja) * | 2011-10-07 | 2014-11-17 | バクスター・ヘルスケヤー・ソシエテ・アノニムBaxter Healthcare SA | Cho−mif遺伝子およびタンパク質の特性評価およびその使用 |
AU2013202693B2 (en) * | 2012-04-16 | 2015-01-22 | Baxalta GmbH | Combination Therapy of Anti-MIF Antibodies and Chemotherapeutics |
AU2013203957B9 (en) * | 2012-04-16 | 2015-10-15 | Baxalta GmbH | Combination Therapy of Anti-MIF Antibodies and Glucocorticoids |
JP2012254994A (ja) * | 2012-07-23 | 2012-12-27 | Trion Pharma Gmbh | 癌治療のための抗体およびグルココルチコイドの組み合わせ |
CN114317666A (zh) * | 2021-11-25 | 2022-04-12 | 中国科学院生态环境研究中心 | 环境污染物的免疫毒性的检测方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
DD230876A1 (de) * | 1983-05-09 | 1985-12-11 | Akad Wissenschaften Ddr | Verfahren zur gewinnung monoklonaler antikoerper gegen human-mif |
JPH0672158B2 (ja) * | 1984-05-24 | 1994-09-14 | チバ−ガイギ− アクチエンゲゼルシヤフト | 精製されたヒトマクロファージ遊走阻止因子 |
US4708937A (en) * | 1984-10-15 | 1987-11-24 | Brigham & Women's Hospital | Purified migration inhibitory factor also having colony stimulating factor activity |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
-
1994
- 1994-05-16 EP EP06017611A patent/EP1741779A3/de not_active Withdrawn
- 1994-05-16 EP EP94916785A patent/EP0702566B1/de not_active Expired - Lifetime
- 1994-05-16 DE DE69435303T patent/DE69435303D1/de not_active Expired - Lifetime
- 1994-05-16 JP JP52576494A patent/JP4708510B2/ja not_active Expired - Fee Related
- 1994-05-16 AT AT94916785T patent/ATE474597T1/de not_active IP Right Cessation
- 1994-05-16 AU AU68345/94A patent/AU692159B2/en not_active Expired
- 1994-05-16 WO PCT/US1994/005433 patent/WO1994026307A1/en active Application Filing
- 1994-05-16 CA CA2163211A patent/CA2163211C/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP1741779A2 (de) | 2007-01-10 |
AU692159B2 (en) | 1998-06-04 |
ATE474597T1 (de) | 2010-08-15 |
EP0702566A4 (de) | 1997-02-26 |
CA2163211C (en) | 2012-05-08 |
EP0702566B1 (de) | 2010-07-21 |
JP4708510B2 (ja) | 2011-06-22 |
CA2163211A1 (en) | 1994-11-24 |
EP0702566A1 (de) | 1996-03-27 |
WO1994026307A1 (en) | 1994-11-24 |
EP1741779A3 (de) | 2010-03-24 |
JPH09500363A (ja) | 1997-01-14 |
AU6834594A (en) | 1994-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69435303D1 (de) | Er behandlung von krankheiten bei denen eine cytok | |
ES2099158T3 (es) | Tratamiento del rechazo de trasplantes o de enfermedades autoinmunitarias y complejo de la formula general x-pro-y-boropro asociada al mismo. | |
DE3587266T2 (de) | Verfahren und system zur entfernung von immunosuppressiven bestandteilen aus saeugetierblut. | |
DE69109560D1 (de) | Fungizide Zusammensetzung zur Behandlung von Saatgut. | |
DE69326776D1 (de) | Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress | |
ATE218854T1 (de) | Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin- abhängigen protein kinase | |
FR2786664B1 (fr) | Procede de traitement de fruits et legumes utilisant l'eugenol et/ou l'isoeugenol et utilisation d'une composition a base d'eugenol et/ou d'isoeugenol | |
DE69109583D1 (de) | Verfahren zur Behandlung von entzündlichen Darmerkrankungen. | |
ATE103918T1 (de) | 5,11-dihydro-6h-dipyrido(3,2-b:2',3'e>(1,4>diazepin-6-one und -thione und ihre verwendung bei der aids-vorbeugung oder behandlung. | |
EP0595995A4 (en) | Arylamidoalkyl-n-hydroxyurea compounds having lipoxygenase inhibitory activity | |
ATE81467T1 (de) | Immunosuppression bei der auf immunotoxin basierten behandlung von menschen. | |
DE59511032D1 (de) | Verwendung von notoginsenosid r1 zur behandlung von endotoxinschock oder herzerkrankungen | |
DE69013871D1 (de) | 4-Benzyl-5-phenyl-2,4-dihydro-3H-1,2,4-triazol-3-one und ihre Verwendung als Antikonvulsiva. | |
DE69839943D1 (de) | Verhinderung von immunreaktivität durch verarmung oder inhibition von antigen-präsentierenden zellen | |
ATE25969T1 (de) | 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten. | |
DE69023006T2 (de) | Verfahren zur behandlung von thrombocytopenie und dafür geeignete pharmazeutische zusammensetzungen. | |
DE3885090T2 (de) | Zusammensetzung und verfahren zur behandlung von hepatitisvirusinfektionen unter verwendung von 1-(2'-deoxy-2'-fluoro-beta-d-arabinofuranosyl)-5-ethyluracil. | |
DE68913995D1 (de) | Zusammensetzung zur behandlung progressiver myopie. | |
DE68908445T2 (de) | Mittel zur Behandlung von Lebererkrankungen. | |
DE69112718D1 (de) | Verfahren und Zusammensetzung zur Behandlung von tierischen Exkrementen. | |
ATE30238T1 (de) | N-acylderivate von peptiden, ihre herstellung und verwendung bei der bekaempfung von krankheiten und mittel dafuer. | |
AT385177B (de) | Fungizide mittel sowie ihre verwendung bei der bekaempfung und behandlung von pilzinfektionen an kulturpflanzen | |
ATE96039T1 (de) | Arzneimittel und ihre verwendung zur behandlung von parasitosen. | |
DE68914886D1 (de) | Mittel zur Behandlung von Raynaud's Krankheit. | |
ATE45271T1 (de) | Mittel und verfahren zur optimierung der gewebemasse von organen innerhalb der genetischen schwankungsbreite bei menschen und tieren. |